RT Journal Article SR Electronic T1 Phosphatase and Tensin Homolog Deleted on Chromosome 10 Suppression Is an Important Process in Peroxisome Proliferator-Activated Receptor-γ Signaling in Adipocytes and Myotubes JF Molecular Pharmacology JO Mol Pharmacol FD American Society for Pharmacology and Experimental Therapeutics SP 1554 OP 1562 DO 10.1124/mol.106.031948 VO 71 IS 6 A1 Ki Young Kim A1 Hyun Sill Cho A1 Won Hoon Jung A1 Sung Soo Kim A1 Hyae Gyeong Cheon YR 2007 UL http://molpharm.aspetjournals.org/content/71/6/1554.abstract AB Peroxisome proliferator-activated receptor-γ (PPARγ) activation enhances insulin sensitivity in type 2 diabetes mellitus. However, downstream mediators of PPARγ activation in adipocytes and myotubes, the most important cell types involved in glucose homeostasis, remained unclear. Here we show by using two synthetic PPARγ agonists (rosiglitazone and KR-62776, a novel PPARγ agonist) that phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a key downstream mediator of PPARγ signaling. The PPARγ agonists down-regulated PTEN expression, resulting in glucose uptake increase in differentiated 3T3-L1 adipocytes and C2C12 skeletal muscle cells. In both cells, PTEN knockdown increased glucose uptake, whereas overexpression abolished the agonist-induced effects. The effects of PPARγ agonists on PTEN expression and glucose uptake disappeared by pretreatment with a PPARγ antagonist or by knockdown of PPARγ expression. In vivo treatment of the agonists to C57BL/6J-ob/ob mice resulted in the reduction of PTEN level in both adipose and skeletal muscle tissues and decreased plasma glucose levels. Thus, these results suggest that PTEN suppression is a key mechanism of the PPARγ-mediated glucose uptake stimulation in insulin-sensitive cells such as adipocytes and skeletal muscle cells, thereby restoring glucose homeostasis in type 2 diabetes. The American Society for Pharmacology and Experimental Therapeutics